Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WGb-0301 in Relapsed and Refractory B-cell Malignant Tumors
NCT07332663Phase 1Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of WGb-0301 in B cell lymphoma and Lymphocytic leukemia, sponsored by Sichuan University. Primary endpoints: Dose Limiting Toxicity at 90 days, Maximum Tolerated Dose at 2 years and 1 more. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
WGb-0301
03
Conditions
B cell lymphomaLymphocytic leukemia
Beyond the preview
Go deeper on NCT07332663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07332663.